MOG (35-55) peptide MEVGWYRSPFSRVVHLYRNGK – Multiple sclerosis peptides
Myelin oligodendrocyte glycoprotein (MOG) is a type I integral membrane glycoprotein of the immunoglobulin superfamily (Ig) found exclusively in mammals. The 26-28 kDa protein is located on the external surface of the oligodendrocyte membrane,mostly on the peripheral lamellae of myelin sheaths of the Central nervous system (CNS)1. The immunodominant 35-55 epitope of MOG (MOG 35-55) is a primary target for both cellular and humoral immune responses1. Anti-MOG antibodies and the abnormal activation of encepalitogenic T cells upon recognition of MOG (35-55) peptide cause the destruction of myelin sheath during Multiple sclerosis (MS),a common inflammatory autoimmune disorder of the CNS1. Although MOG is a minor component of the CNS,the 35-55 epitope of MOG (MOG 35-55) is strongly immunogenic and therefore is widely used for in vivo biological evaluation and immunological studies of the Experimental Autoimmune Encephalomyelitis (EAE),a mouse animal model for T-cell-mediated inflammatory demyelinating autoimmune diseases of the CNS1. Administration of MOG35-55 peptide in mice produces anti-MOG antibodies that cause demyelination and a chronic Experimental Autoimmune Encephalomyelitis1. Anti-MOG antibodies are observed in cerebrospinal fluid (CFS) and the serum of MS pateints. There is a direct correlation between the severity of the MS symptomes and anti-MOG titers. The progression of Multiple sclerosis is rapid and relapses occur more frequently in presence of anti-MOG antibodies. Therefore,anti-MOG antibodies are an indicator for the prognosis and progression of Multiple sclerosis1. They can be detected by MOG (35-55) epitope-coated ELISA for quantification. MOG (35-55)-induced EAE models can help elucidating the immunopathological mechanism of Multiple sclerosis and promote the developement of novel therapeutics. One therapeutic approach consists on the administration of a mixture of peptides,representing immunodominant epitopes of different myelin proteins including MOG peptide at a proper dose to modulate the immune response and induce tolerance1.
Technical specification
| Sequence | MEVGWYRSPFSRVVHLYRNGK |
|---|---|
| MW | 2 581.95 g/mol (C₁₁₈H₁₇₇N₃₅O₂₉S) |
| Purity | > 95% |
| Counter-ion | TFA Salts (see option TFA removal) |
| Delivery format | Freeze dried in propylene 2mL microtubes |
Price
| Product | Size | Price € | Price $ |
|---|---|---|---|
| NJ023-1MG | 1 mg | 77 € | 96 $ |
| NJ023-5MG | 5 mg | 270 € | 337 $ |
| NJ023-2*5MG | 2x5 mg | 385 € | 481 $ |
| NJ023-5*10MG | 5x10 mg | 737 € | 921 $ |
